MS is misdiagnosed too often, which leaves some people who don't have MS receiving expensive disease-modifying therapy that they don't need, while leaving other people who do have MS still not receiving treatment with a disease-modifying therapy that will slow disability progression and preserve their quality of life longer.

My guest, Dr. Andrew Solomon, is the lead author of a paper published by a team of international experts that provides updated guidance for healthcare professionals on clinical approaches to diagnosing MS. Dr. Solomon joins me to discuss why MS can be difficult to diagnose and how that situation can be improved upon.

We're also sharing the results of a study that showed how neurofilament light chain levels in the blood can predict MS disability progression one or two years before that worsening occurs.

For the past five years, we've been following the path of an investigative stem cell therapy through clinical trials. We'll tell you why the company behind this therapy announced it was stopping its Phase 2 trial.

If you're a female living with MS, we're sharing an invitation for you to participate in an important online survey about a topic that's too often overlooked.

And we'll tell you about the results of a study that underscore the value and importance of staying on your disease-modifying therapy.

We have a lot to talk about! Are you ready for RealTalk MS??!

свернуть